Adrian Bot
20Patents
7h-index
23Co-inventors
69Inventor score
Filing activity: Nov 22, 1996 → Feb 20, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6630169B1 | Particulate delivery systems and methods of use | Emerging Cross-Sectional Technologies | 107 | Expired |
| US9855298B2 | Methods of conditioning patients for T cell therapy | Chemistry; Metallurgy | 29 | Active |
| US6204250A | Immunization of infants | Emerging Cross-Sectional Technologies | 21 | Expired |
| US8703142B2 | Methods to bypass CD4+ cells in the induction of an immune response | Chemistry; Metallurgy | 15 | Active |
| US8653237B2 | Peptide analogues | Human Necessities | 12 | Active |
| US8354380B2 | NY-ESO-1 peptide analogs | Human Necessities | 8 | Active |
| US8084592B2 | Multivalent entrain-and-amplify immunotherapeutics for carcinoma | Human Necessities | 8 | Active |
| US7511119B2 | PRAME peptide analogues | Human Necessities | 6 | Active |
| US7141236B2 | Methods and compositions for delivering macromolecules to or via the respiratory tract | Human Necessities | 5 | Expired |
| US7511118B2 | PSMA peptide analogues | Human Necessities | 4 | Active |
| US10322146B2 | Methods of conditioning patients for T cell therapy | Chemistry; Metallurgy | 4 | Active |
| US7605227B2 | Melanoma antigen peptide analogues | Human Necessities | 4 | Active |
| US8809290B2 | Methods and compositions to generate and control the effector profile of T cells by simultaneous loading and activation of selected subsets of antigen presenting cells | Chemistry; Metallurgy | 2 | Active |
| US11779601B2 | Diagnostic methods for T cell therapy | Physics | 1 | Active |
| US11491187B2 | Methods of conditioning patients for T cell therapy | Chemistry; Metallurgy | 1 | Active |
| US8674081B2 | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | Human Necessities | 1 | Active |
| US7999088B2 | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | Human Necessities | 1 | Active |
| US12156887B2 | Chimeric receptor T cell treatment using characteristics of the tumor microenvironment | Physics | 0 | Active |
| US11357796B2 | Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells | Human Necessities | 0 | Active |
| US12252701B2 | Chimeric antigen receptor T cell therapy | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.